[Peripheral muscle dysfunction in chronic obstructive pulmonary disease].
Patients with chronic obstructive pulmonary disease (COPD) often develop systemic complications of their disease. Peripheral muscle dysfunction is one such complication and is characterised by atrophy, weakness, and low oxidative capacity. These muscle changes influence exercise tolerance and quality of life independent of the impairment in lung function. In the following article, the evidence for peripheral muscle dysfunction in patients with COPD and the possible clinical implications of this problem will be discussed. Lastly, the available therapeutic options to improve peripheral muscle function in COPD will be reviewed.
Maltais
F
F
Institut universitaire de cardiologie et de pneumologie, Hôpital Laval, Université Laval, Québec, Canada.
Leblanc
P
P
Jobin
J
J
Casaburi
R
R
D000203:Activities of Daily Living; D045930:Anabolic Agents / Q000627:therapeutic use; D004734:Energy Metabolism; D005081:Exercise Therapy; D017079:Exercise Tolerance; D006801:Humans; D007249:Inflammation; D018908:Muscle Weakness / Q000175:diagnosis / Q000209:etiology* / Q000523:psychology / Q000628:therapy; D009133:Muscular Atrophy / Q000175:diagnosis / Q000209:etiology* / Q000523:psychology / Q000628:therapy; D009752:Nutritional Status; D018529:Nutritional Support; D010102:Oxygen Inhalation Therapy; D010807:Physical Endurance; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D011788:Quality of Life; D012307:Risk Factors; D014057:Tomography, X-Ray Computed
D045930:Anabolic Agents